Mezzion Pharma, a Seoul, South Korea-based pharmaceutical company, raised nearly $40M in funding.
The investment was a paid-in capital increase from BRV Capital Management.
The company intends to use the capital to fund FUEL-2, their confirmatory phase 3 clinical trial, along with future commercialization and regulatory submissions in other countries including Europe.
Led by Founder and CEO Mr. Dong-Hyun Park, Mezzion Pharma is a pharmaceutical company that is focused on discovering, developing, and commercializing novel therapeutics in the field of rare pediatric diseases. A publicly listed pharmaceutical company in Korea on the Korean stock exchange under (140410:KOSDAQ), the company is looking to bring to market JURVIGO (udenafil), a phosphodiesterase type 5 inhibitor (“PDE-5 inhibitor”), for specific use in the estimated global 70K single ventricle congenital heart disease (“SV-CHD”) patients with ages of twelve and above who have undergone Fontan surgical palliation.
Mezzion and its subsidiary, Mezzion Pharmaceuticals, Inc., have administrative offices in Deerfield, Illinois and Boca Raton, Florida.
FinSMEs
25/04/2023